ALDX - Aldeyra Therapeutics, Inc.
IEX Last Trade
4.81
0.050 1.040%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$4.76
0.05
1.05%
Fundamental analysis
23%
Profitability
25%
Dept financing
7%
Liquidity
50%
Performance
19%
Performance
5 Days
-2.56%
1 Month
-4.33%
3 Months
-11.94%
6 Months
42.79%
1 Year
36.64%
2 Year
-28.06%
Key data
Stock price
$4.81
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.82 - $6.55
52 WEEK CHANGE
$30.99
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/01/2024
Company detail
CEO: Todd C. Brady
Region: US
Website: aldeyra.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aldeyra.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.
Recent news